Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autoimmune disorder that manifests as different lupus-specific skin disorders; it can occur with systemic lupus erythematosus, or as a singular disease.
Biomarker and diagnostic research for cutaneous lupus erythematosus has been reported in the published literature.
25 clinical trials registered, 11 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE4, 7 PHASE3, 5 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT07440537](https://clinicaltrials.gov/study/NCT07440537) |
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 11:33 PM UTC
Genetic and Rare Diseases Info Center
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
PHASE2 |
Beijing InnoCare Pharma Tech Co., Ltd. |
RECRUITING |
[NCT07260877](https://clinicaltrials.gov/study/NCT07260877) | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | PHASE2 | Ventus Therapeutics U.S., Inc. | RECRUITING |
[NCT06927219](https://clinicaltrials.gov/study/NCT06927219) | Research Accelerated by You Lupus Registry | — | Lupus Foundation of America | RECRUITING |
[NCT07355218](https://clinicaltrials.gov/study/NCT07355218) | A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2) | PHASE3 | EMD Serono Research & Development Institute, Inc. | RECRUITING |
[NCT07455578](https://clinicaltrials.gov/study/NCT07455578) | Study of S-4321 in Participants With an Autoimmune or Immune-mediated Disease | PHASE1 | Seismic Therapeutic AU Pty Ltd | RECRUITING |
219 publications have been identified in PubMed for cutaneous lupus erythematosus. Research spans Review / Meta-Analysis (30%), Case Report / Case Series (20%), and Epidemiology / Natural History (12%).
Research Type | Count | % of Total |
|---|---|---|
Research summaries | 57 | 30% |
Patient case studies | 38 | 20% |
Disease patterns and progression | 23 | 12% |
Laboratory research | 20 | 11% |
Clinical study results | 19 | 10% |
Testing and diagnosis research | 14 | 7% |
Other research | 13 | 7% |
New treatment approaches | 3 | 2% |
Litaiem N (2026). [PMID: 41877623](https://pubmed.ncbi.nlm.nih.gov/41877623/). *Int J Dermatol*. [Epidemiology / Natural History]
Wang Q (2026). [PMID: 41869391](https://pubmed.ncbi.nlm.nih.gov/41869391/). *J Transl Autoimmun*. [Review / Meta-Analysis]
Wang XM (2026). [PMID: 41575073](https://pubmed.ncbi.nlm.nih.gov/41575073/). *J Eur Acad Dermatol Venereol*. [Case Report / Case Series]
Bosch-Amate X (2026). [PMID: 41691405](https://pubmed.ncbi.nlm.nih.gov/41691405/). *J Dtsch Dermatol Ges*. [Case Report / Case Series]
Morand EF (2026). [PMID: 42107375](https://pubmed.ncbi.nlm.nih.gov/42107375/). *Lancet Rheumatol*. [Clinical Trial Publication]
Saberi F (2026). [PMID: 42125165](https://pubmed.ncbi.nlm.nih.gov/42125165/). *Clin Case Rep*. [Case Report / Case Series]
de La Rochefoucauld J (2026). [PMID: 40914462](https://pubmed.ncbi.nlm.nih.gov/40914462/). *J Am Acad Dermatol*. [Epidemiology / Natural History]
Werth VP (2026). [PMID: 42254019](https://pubmed.ncbi.nlm.nih.gov/42254019/). *Front Immunol*. [Review / Meta-Analysis]
Saeed SM (2026). [PMID: 41542308](https://pubmed.ncbi.nlm.nih.gov/41542308/). *JAAD Case Rep*. [Case Report / Case Series]
Lu G (2026). [PMID: 41588246](https://pubmed.ncbi.nlm.nih.gov/41588246/). *Nat Rev Rheumatol*. [Review / Meta-Analysis]
AI-curated news mentioning cutaneous lupus erythematosus
Updated Mar 30, 2026
Biogen's drug for cutaneous lupus erythematosus shows promising results in reducing disease activity, marking a significant advancement in their immunology and inflammation pipeline. Analysts view this as a crucial derisking step for the company's future prospects.